Fusion Antibodies plc (LSE:FAB) reported a year of operational progress for the period ending 31 March 2026, with revenue rising about 9% to £2.13m. Gross margin more than doubled to 50%, while cash reserves increased to £1.04m, supported by proceeds from an intellectual property sale and non-dilutive grant funding.
Strategic Progress Through IP and Collaborations
The company strengthened its competitive position with the award of a new U.S. patent covering its OptiMAL platform. It also expanded its network of collaborations, including ongoing work with the National Cancer Institute and Queen’s University Belfast, alongside deeper engagement with U.S.-based biotechnology clients.
In addition, Fusion Antibodies secured new projects with major global pharmaceutical companies, aiming to diversify its revenue base and build a stronger pipeline for future growth despite challenging market conditions.
Outlook Remains Constrained by Profitability Challenges
While operational indicators show improvement, the company’s outlook continues to be weighed down by weak overall financial performance and valuation concerns.
Although some positive technical momentum is evident, the lack of profitability and a negative P/E ratio present ongoing risks. Limited additional insight from earnings calls or major corporate developments further constrains visibility.
More About Fusion Antibodies plc
Fusion Antibodies plc is a Belfast-based contract research organisation focused on pre-clinical antibody discovery, engineering, and supply for therapeutic and diagnostic applications.
Listed on AIM, the company provides a range of services including antibody generation, development, production, characterisation, and humanisation, working with biotechnology firms and global pharmaceutical clients.
Leave a Reply